دورية أكاديمية
Identification of non-mutated neoantigens presented by TAP-deficient tumors.
| العنوان: | Identification of non-mutated neoantigens presented by TAP-deficient tumors. |
|---|---|
| المؤلفون: | Marijt KA; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Blijleven L; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Verdegaal EME; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Kester MG; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands., Kowalewski DJ; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium, German Cancer Research Center, Tübingen, Germany., Rammensee HG; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium, German Cancer Research Center, Tübingen, Germany., Stevanović S; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium, German Cancer Research Center, Tübingen, Germany., Heemskerk MHM; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands., van der Burg SH; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., van Hall T; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands T.van_Hall@lumc.nl. |
| المصدر: | The Journal of experimental medicine [J Exp Med] 2018 Sep 03; Vol. 215 (9), pp. 2325-2337. Date of Electronic Publication: 2018 Aug 16. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Rockefeller University Press Country of Publication: United States NLM ID: 2985109R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-9538 (Electronic) Linking ISSN: 00221007 NLM ISO Abbreviation: J Exp Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Rockefeller University Press |
| مواضيع طبية MeSH: | Antigen Presentation* , Tumor Escape*, ATP-Binding Cassette Transporters/*deficiency , Antigens, Neoplasm/*immunology , CD8-Positive T-Lymphocytes/*immunology , HLA-A2 Antigen/*immunology , LDL-Receptor Related Protein-Associated Protein/*immunology , Neoplasm Proteins/*immunology , Neoplasms/*immunology, ATP-Binding Cassette Transporters/immunology ; CD8-Positive T-Lymphocytes/pathology ; Female ; Humans ; Male ; Neoplasms/pathology ; Tumor Cells, Cultured |
| مستخلص: | Most T cell-based immunotherapies of cancer depend on intact antigen presentation by HLA class I molecules (HLA-I). However, defects in the antigen-processing machinery can cause downregulation of HLA-I, rendering tumor cells resistant to CD8 + T cells. Previously, we demonstrated that a unique category of cancer antigens is selectively presented by tumor cells deficient for the peptide transporter TAP, enabling a specific attack of such tumors without causing immunopathology in mouse models. With a novel combinatorial screening approach, we now identify 16 antigens of this category in humans. These HLA-A*02:01 presented peptides do not derive from the mutanome of cancers, but are of "self" origin and therefore constitute universal neoantigens. Indeed, CD8 + T cells specific for the leader peptide of the ubiquitously expressed LRPAP1 protein recognized TAP-deficient, HLA-I low lymphomas, melanomas, and renal and colon carcinomas, but not healthy counterparts. In contrast to personalized mutanome-targeted therapies, these conserved neoantigens and their cognate receptors can be exploited for immune-escaped cancers across diverse histological origins. (© 2018 Marijt et al.) |
| التعليقات: | Comment in: J Exp Med. 2018 Sep 3;215(9):2233-2234. (PMID: 30131364) |
| References: | Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3429-33. (PMID: 1565634) J Immunol. 2011 Dec 1;187(11):5532-9. (PMID: 22025554) BMC Immunol. 2008 Jan 22;9:1. (PMID: 18211710) Nat Rev Immunol. 2011 Nov 11;11(12):823-36. (PMID: 22076556) Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3825-30. (PMID: 18308940) Annu Rev Immunol. 2013;31:443-73. (PMID: 23298205) Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900) J Immunother. 1998 Mar;21(2):127-31. (PMID: 9551364) J Immunol. 2000 Dec 1;165(11):6229-34. (PMID: 11086057) Eur J Immunol. 2011 Nov;41(11):3114-24. (PMID: 21898382) J Immunol. 2013 Oct 15;191(8):4020-8. (PMID: 24048903) J Mol Biol. 2004 May 14;338(5):1027-36. (PMID: 15111065) Sci Rep. 2017 May 23;7(1):2290. (PMID: 28536458) Nature. 2017 Aug 31;548(7669):537-542. (PMID: 28783722) Nature. 2017 Nov 23;551(7681):525-528. (PMID: 29107940) Nature. 1992 Apr 2;356(6368):443-6. (PMID: 1557127) Curr HIV Res. 2003 Jul;1(3):287-94. (PMID: 15046253) J Biol Chem. 2011 Mar 18;286(11):9321-37. (PMID: 21247888) Nat Med. 2006 Apr;12(4):417-24. (PMID: 16550190) Mol Cell Biol. 2007 Nov;27(22):7886-94. (PMID: 17875943) Scand J Immunol. 1999 Oct;50(4):420-6. (PMID: 10520183) Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4615-22. (PMID: 20660719) Nat Med. 2013 Jun;19(6):747-52. (PMID: 23644516) Cancer Res. 2007 Sep 15;67(18):8450-5. (PMID: 17875682) J Transl Med. 2005 Sep 20;3:35. (PMID: 16174302) Front Immunol. 2018 Jan 25;9:60. (PMID: 29422902) J Immunol. 2009 Oct 1;183(7):4639-47. (PMID: 19752221) Nat Commun. 2017 May 31;8:15440. (PMID: 28561041) Nat Methods. 2014 Aug;11(8):783-784. (PMID: 25075903) J Immunol. 2007 Jun 15;178(12):7932-42. (PMID: 17548631) Cell. 2016 Oct 6;167(2):397-404.e9. (PMID: 27667683) Nat Commun. 2017 Nov 23;8(1):1738. (PMID: 29170503) Mol Immunol. 2018 Apr 4;:null. (PMID: 29627136) Bioinformatics. 2016 Feb 15;32(4):511-7. (PMID: 26515819) Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10119-24. (PMID: 18626012) Eur J Immunol. 2012 Jun;42(6):1405-16. (PMID: 22678897) J Clin Invest. 2016 Feb;126(2):784-94. (PMID: 26784543) Trends Cell Biol. 1998 Oct;8(10):410-5. (PMID: 9789330) J Immunol. 1996 May 1;156(9):3308-14. (PMID: 8617954) Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375) Immunogenetics. 1999 Nov;50(3-4):201-12. (PMID: 10602880) Oncoimmunology. 2017 Nov 20;7(3):e1382793. (PMID: 29399388) Clin Dev Immunol. 2012;2012:153863. (PMID: 23227083) Cancer Res. 2001 Aug 1;61(15):5850-6. (PMID: 11479225) J Immunol. 2010 Mar 15;184(6):2985-98. (PMID: 20164418) Curr Opin Immunol. 2016 Apr;39:44-51. (PMID: 26796069) N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843) J Immunol. 1993 Oct 1;151(7):3407-19. (PMID: 8376783) Cell. 2016 Apr 7;165(2):276-87. (PMID: 27058662) N Engl J Med. 2014 Dec 4;371(23):2189-2199. (PMID: 25409260) Protein Sci. 2003 May;12(5):1007-17. (PMID: 12717023) Cancer Discov. 2017 Feb;7(2):188-201. (PMID: 27903500) |
| سلسلة جزيئية: | SWISSPROT Q9Y282; Q9C0H2; P01591; P15289; Q9BXX0; O60613; P29459; P00739; Q6MZW2; P40259; Q9Y5G7; Q9NUB4; P02743 |
| المشرفين على المادة: | 0 (ATP-Binding Cassette Transporters) 0 (Antigens, Neoplasm) 0 (HLA-A*02:01 antigen) 0 (HLA-A2 Antigen) 0 (LDL-Receptor Related Protein-Associated Protein) 0 (Neoplasm Proteins) 0 (transporter associated with antigen processing (TAP)) |
| تواريخ الأحداث: | Date Created: 20180818 Date Completed: 20190904 Latest Revision: 20210105 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC6122969 |
| DOI: | 10.1084/jem.20180577 |
| PMID: | 30115740 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1540-9538 |
|---|---|
| DOI: | 10.1084/jem.20180577 |